[{"indications": "Indications\u00a0severe chronic pain, breakthrough pain; parenteral indications (section 15.1.4.3)", "name": "FENTANYL Patches", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "FENTANYL", "Patches"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also diabetes\r\nmellitus, impaired consciousness, cerebral tumour; see also %s\n(From Patches: British National Formulary)\nPatchesTransdermal fentanylFever or external heat\u00a0Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption)Respiratory depression\u00a0Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patientsCounselling\u00a0Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdosage. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.Prescriptions\u00a0Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write \u2018Fentanyl 25 patches\u2019 to prescribe patches that release fentanyl 25\u00a0micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. \u2018one patch to be applied every 72 hours\u2019. The total quantity of patches to be supplied should be written in words and figures.FentanylDurogesic DTrans\u00ae", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; also\r\nabdominal pain, dyspepsia, diarrhoea, gastro-oesophageal reflux disease,\r\nstomatitis, anorexia, hypertension, vasodilation, dyspnoea, aesthenia,\r\nmyoclonus, anxiety, tremor, appetite changes, rhinitis, pharyngitis,\r\nparaesthesia, application-site reactions; less commonly ileus, flatulence, hypoventilation, impaired concentration, impaired\r\ncoordination, amnesia, speech disorder, malaise, seizures, pyrexia,\r\nthirst, blood disorders (including thrombocytopenia), chills; rarely hiccups; very rarely arrhythmia,\r\napnoea, haemoptysis, ataxia, delusions, bladder pain", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/27054.htm", "doses": ["Chronic intractable pain, by transdermal route, apply to dry, non-irritated, non-irradiated, non-hairy skin on\r\ntorso or upper arm, removing after 72 hours and siting replacement\r\npatch on a different area (avoid using the same area for several days). adult over 16 years not currently treated with a strong opioid analgesic (but see Transdermal Fentanyl), initial dose, one \u201812\u2019 or \u201825\u00a0micrograms/hour\u2019\r\npatch replaced after 72 hours; adult and child over 2 years currently\r\ntreated with a strong opioid analgesic, initial dose based\r\non previous 24-hour opioid requirement (consult product literature)", "When starting, evaluation of the\r\nanalgesic effect should not be made before the system\r\nhas been worn for 24 hours (to allow for the gradual\r\nincrease in plasma-fentanyl concentration)\u2014previous\r\nanalgesic therapy should be phased out gradually from time of first\r\npatch application; if necessary dose should be adjusted at 48\u201372-hour\r\nintervals in steps of 12\u201325\u00a0micrograms/hour. More than one patch may\r\nbe used at a time (but applied at the same time to\r\navoid confusion)\u2014consider additional or alternative analgesic therapy\r\nif dose required exceeds 300\u00a0micrograms/hour (important: it may take up to 25 hours for the plasma-fentanyl concentration to decrease by 50%\u2014replacement opioid therapy should\r\nbe initiated at a low dose and increased gradually).", "In view of the long duration\r\nof action, patients who have had severe side-effects should be monitored\r\nfor up to 24 hours after patch removal", "Breakthrough pain, see under oral preparations", "(from oral morphine to transdermal\r\nfentanyl) see Prescribing in Palliative\r\nCare", "Name[Durogesic DTrans\u00ae (Janssen) ] Patches, self-adhesive, transparent, fentanyl, \u201812\u2019 patch (releasing approx. 12\u00a0micrograms/hour\r\nfor 72 hours), net price 5 = \u00a313.69; \u201825\u2019 patch (releasing approx.\r\n25\u00a0micrograms/hour for 72 hours), 5 = \u00a319.59; \u201850\u2019 patch (releasing\r\napprox. 50\u00a0micrograms/hour for 72 hours), 5 = \u00a336.59; \u201875\u2019 patch (releasing\r\napprox. 75\u00a0micrograms/hour for 72 hours), 5 = \u00a350.99; \u2018100\u2019 patch\r\n(releasing approx. 100\u00a0micrograms/hour for 72 hours), 5 = \u00a362.89. \r\n    Label:\r\n    2, counselling, administration"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour."}, {"indications": "Indications\u00a0analgesia during operation, enhancement\r\nof anaesthesia; respiratory depressant in assisted respiration; analgesia\r\nin other situations (section 4.7.2)", "name": "FENTANYL - SEDATIVE AND ANALGESIC PERI-OPERATIVE DRUGS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "15 Anaesthesia", "15.1 General anaesthesia", "15.1.4 Sedative and analgesic peri-operative drugs", "15.1.4.3 Opioid analgesics", "FENTANYL"], "cautions": "Cautions\u00a0see Fentanyl, section 4.7.2 and notes above", "side-effects": "Side-effects\u00a0see Fentanyl, section 4.7.2 and notes above; also myoclonic movements; less commonly laryngospasm; rarely asystole\r\nand insomnia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6628.htm", "doses": ["To avoid excessive dosage in obese patients,\r\ndose may need to be calculated on the basis of ideal body-weight", "By slow intravenous injection, with\r\nspontaneous respiration, adult and child over 12 years, initially 50\u2013100\u00a0micrograms\r\n(max. 200\u00a0micrograms on specialist advice), then 25\u201350\u00a0micrograms\r\nas required; child 1 month\u201312 years\r\nsee BNF for Children", "With assisted ventilation, adult and child over 12 years, initially\r\n0.3\u20133.5\u00a0mg, then 100\u2013200\u00a0micrograms as required; child 1 month\u201312 years see BNF for Children", "By intravenous infusion, with spontaneous\r\nrespiration, adult, 3\u20134.8\u00a0micrograms/kg/hour\r\nadjusted according to response", "With assisted ventilation, adult, initially 10\u00a0micrograms/kg over 10 minutes then 6\u00a0micrograms/kg/hour\r\nadjusted according to response; may require up to 180\u00a0micrograms/kg/hour\r\nduring cardiac surgery; child 1 month\u201318\r\nyears see BNF for Children"], "pregnancy": "Pregnancy\u00a0see notes in section 4.7.2"}, {"indications": "Indications\u00a0severe chronic pain, breakthrough pain; parenteral indications (section 15.1.4.3)", "name": "FENTANYL Nasal spray", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "FENTANYL", "Nasal spray"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also diabetes\r\nmellitus, impaired consciousness, cerebral tumour; see also %s\n(From Patches: British National Formulary)\nPatchesTransdermal fentanylFever or external heat\u00a0Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption)Respiratory depression\u00a0Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patientsCounselling\u00a0Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdosage. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.Prescriptions\u00a0Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write \u2018Fentanyl 25 patches\u2019 to prescribe patches that release fentanyl 25\u00a0micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. \u2018one patch to be applied every 72 hours\u2019. The total quantity of patches to be supplied should be written in words and figures.FentanylDurogesic DTrans\u00ae", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; also\r\nabdominal pain, dyspepsia, diarrhoea, gastro-oesophageal reflux disease,\r\nstomatitis, anorexia, hypertension, vasodilation, dyspnoea, aesthenia,\r\nmyoclonus, anxiety, tremor, appetite changes, rhinitis, pharyngitis,\r\nparaesthesia, application-site reactions; less commonly ileus, flatulence, hypoventilation, impaired concentration, impaired\r\ncoordination, amnesia, speech disorder, malaise, seizures, pyrexia,\r\nthirst, blood disorders (including thrombocytopenia), chills; rarely hiccups; very rarely arrhythmia,\r\napnoea, haemoptysis, ataxia, delusions, bladder pain", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/204140.htm", "doses": ["Chronic intractable pain, by transdermal route, apply to dry, non-irritated, non-irradiated, non-hairy skin on\r\ntorso or upper arm, removing after 72 hours and siting replacement\r\npatch on a different area (avoid using the same area for several days). adult over 16 years not currently treated with a strong opioid analgesic (but see Transdermal Fentanyl), initial dose, one \u201812\u2019 or \u201825\u00a0micrograms/hour\u2019\r\npatch replaced after 72 hours; adult and child over 2 years currently\r\ntreated with a strong opioid analgesic, initial dose based\r\non previous 24-hour opioid requirement (consult product literature)", "When starting, evaluation of the\r\nanalgesic effect should not be made before the system\r\nhas been worn for 24 hours (to allow for the gradual\r\nincrease in plasma-fentanyl concentration)\u2014previous\r\nanalgesic therapy should be phased out gradually from time of first\r\npatch application; if necessary dose should be adjusted at 48\u201372-hour\r\nintervals in steps of 12\u201325\u00a0micrograms/hour. More than one patch may\r\nbe used at a time (but applied at the same time to\r\navoid confusion)\u2014consider additional or alternative analgesic therapy\r\nif dose required exceeds 300\u00a0micrograms/hour (important: it may take up to 25 hours for the plasma-fentanyl concentration to decrease by 50%\u2014replacement opioid therapy should\r\nbe initiated at a low dose and increased gradually).", "In view of the long duration\r\nof action, patients who have had severe side-effects should be monitored\r\nfor up to 24 hours after patch removal", "Breakthrough pain, see under oral preparations", "(from oral morphine to transdermal\r\nfentanyl) see Prescribing in Palliative\r\nCare", "Name[Instanyl\u00ae (Nycomed)  ] Nasal spray, fentanyl (as citrate)\r\n50\u00a0micrograms/metered spray, net price single-dose pack = \u00a35.95, 10-dose\r\npack = \u00a359.50, 20-dose pack = \u00a3119.00; 100\u00a0micrograms/metered spray,\r\nsingle-dose pack = \u00a35.95, 10-dose pack = \u00a359.50, 20-dose pack = \u00a3119.00;\r\n200\u00a0micrograms/metered spray, single-dose pack = \u00a35.95, 10-dose pack\r\n= \u00a359.50, 20-dose pack = \u00a3119.00. \r\n    Label:\r\n    2, counselling, administrationDose\u00a0breakthrough pain in patients receiving opioid therapy\r\nfor chronic cancer pain, adult over\r\n18 years, initially 50\u00a0micrograms into one nostril, repeated once\r\nif necessary after 10 minutes; adjust dose according to response;\r\nmax. 2 sprays for each pain episode and minimum 4 hours between treatment\r\nof each pain episodeNote\u00a0If more than 4 breakthrough pain episodes\r\ndaily, adjust background analgesiaCounselling\u00a0Patient should sit or stand during\r\nadministration. Avoid concomitant use of other nasal preparationsThe Scottish Medicines\r\nConsortium has advised that Instanyl\u00ae nasal spray should\r\nbe restricted for use within NHS Scotland for the management of breakthrough\r\npain in adult patients using opioid therapy for chronic cancer pain,\r\nwhen other short-acting opioids are unsuitable"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour."}, {"indications": "Indications\u00a0severe chronic pain, breakthrough pain; parenteral indications (section 15.1.4.3)", "name": "FENTANYL Lozenges", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "FENTANYL", "Lozenges"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also diabetes\r\nmellitus, impaired consciousness, cerebral tumour; see also %s\n(From Patches: British National Formulary)\nPatchesTransdermal fentanylFever or external heat\u00a0Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption)Respiratory depression\u00a0Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patientsCounselling\u00a0Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdosage. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.Prescriptions\u00a0Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write \u2018Fentanyl 25 patches\u2019 to prescribe patches that release fentanyl 25\u00a0micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. \u2018one patch to be applied every 72 hours\u2019. The total quantity of patches to be supplied should be written in words and figures.FentanylDurogesic DTrans\u00ae", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; also\r\nabdominal pain, dyspepsia, diarrhoea, gastro-oesophageal reflux disease,\r\nstomatitis, anorexia, hypertension, vasodilation, dyspnoea, aesthenia,\r\nmyoclonus, anxiety, tremor, appetite changes, rhinitis, pharyngitis,\r\nparaesthesia, application-site reactions; less commonly ileus, flatulence, hypoventilation, impaired concentration, impaired\r\ncoordination, amnesia, speech disorder, malaise, seizures, pyrexia,\r\nthirst, blood disorders (including thrombocytopenia), chills; rarely hiccups; very rarely arrhythmia,\r\napnoea, haemoptysis, ataxia, delusions, bladder pain", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106077.htm", "doses": ["Chronic intractable pain, by transdermal route, apply to dry, non-irritated, non-irradiated, non-hairy skin on\r\ntorso or upper arm, removing after 72 hours and siting replacement\r\npatch on a different area (avoid using the same area for several days). adult over 16 years not currently treated with a strong opioid analgesic (but see Transdermal Fentanyl), initial dose, one \u201812\u2019 or \u201825\u00a0micrograms/hour\u2019\r\npatch replaced after 72 hours; adult and child over 2 years currently\r\ntreated with a strong opioid analgesic, initial dose based\r\non previous 24-hour opioid requirement (consult product literature)", "When starting, evaluation of the\r\nanalgesic effect should not be made before the system\r\nhas been worn for 24 hours (to allow for the gradual\r\nincrease in plasma-fentanyl concentration)\u2014previous\r\nanalgesic therapy should be phased out gradually from time of first\r\npatch application; if necessary dose should be adjusted at 48\u201372-hour\r\nintervals in steps of 12\u201325\u00a0micrograms/hour. More than one patch may\r\nbe used at a time (but applied at the same time to\r\navoid confusion)\u2014consider additional or alternative analgesic therapy\r\nif dose required exceeds 300\u00a0micrograms/hour (important: it may take up to 25 hours for the plasma-fentanyl concentration to decrease by 50%\u2014replacement opioid therapy should\r\nbe initiated at a low dose and increased gradually).", "In view of the long duration\r\nof action, patients who have had severe side-effects should be monitored\r\nfor up to 24 hours after patch removal", "Breakthrough pain, see under oral preparations", "(from oral morphine to transdermal\r\nfentanyl) see Prescribing in Palliative\r\nCare", "Name[Actiq\u00ae (Flynn) ] Lozenge (buccal), with oromucosal applicator, fentanyl (as citrate)\r\n200\u00a0micrograms, net price 3 = \u00a317.54, 30 = \u00a3175.34; 400\u00a0micrograms,\r\n3 = \u00a317.54, 30 = \u00a3175.34; 600\u00a0micrograms, 3 = \u00a317.54, 30 = \u00a3175.34;\r\n800\u00a0micrograms, 3 = \u00a317.54, 30 = \u00a3175.34; 1.2\u00a0mg, 3 = \u00a317.54, 30 =\r\n\u00a3175.34; 1.6\u00a0mg, 3 = \u00a317.54, 30 = \u00a3175.34. \r\n    Label:\r\n    2Dose\u00a0breakthrough pain in patients receiving opioid therapy\r\nfor chronic cancer pain, adult and child over 16 years initially 200\u00a0micrograms (over\r\n15 minutes) repeated if necessary 15 minutes after first dose (no\r\nmore than 2 dose units for each pain episode); if adequate pain relief\r\nnot achieved with 1 dose unit for consecutive breakthrough pain episodes,\r\nincrease the strength of the dose unit until adequate pain relief\r\nachieved with 4 lozenges or less dailyNote\u00a0If more than 4 episodes of breakthrough pain\r\neach day, adjust background analgesia"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour."}, {"indications": "Indications\u00a0severe chronic pain, breakthrough pain; parenteral indications (section 15.1.4.3)", "name": "FENTANYL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "FENTANYL"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also diabetes\r\nmellitus, impaired consciousness, cerebral tumour; see also %s\n(From Patches: British National Formulary)\nPatchesTransdermal fentanylFever or external heat\u00a0Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption)Respiratory depression\u00a0Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patientsCounselling\u00a0Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdosage. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.Prescriptions\u00a0Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write \u2018Fentanyl 25 patches\u2019 to prescribe patches that release fentanyl 25\u00a0micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. \u2018one patch to be applied every 72 hours\u2019. The total quantity of patches to be supplied should be written in words and figures.FentanylDurogesic DTrans\u00ae", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; also\r\nabdominal pain, dyspepsia, diarrhoea, gastro-oesophageal reflux disease,\r\nstomatitis, anorexia, hypertension, vasodilation, dyspnoea, aesthenia,\r\nmyoclonus, anxiety, tremor, appetite changes, rhinitis, pharyngitis,\r\nparaesthesia, application-site reactions; less commonly ileus, flatulence, hypoventilation, impaired concentration, impaired\r\ncoordination, amnesia, speech disorder, malaise, seizures, pyrexia,\r\nthirst, blood disorders (including thrombocytopenia), chills; rarely hiccups; very rarely arrhythmia,\r\napnoea, haemoptysis, ataxia, delusions, bladder pain", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201310.htm", "doses": ["Chronic intractable pain, by transdermal route, apply to dry, non-irritated, non-irradiated, non-hairy skin on\r\ntorso or upper arm, removing after 72 hours and siting replacement\r\npatch on a different area (avoid using the same area for several days). adult over 16 years not currently treated with a strong opioid analgesic (but see Transdermal Fentanyl), initial dose, one \u201812\u2019 or \u201825\u00a0micrograms/hour\u2019\r\npatch replaced after 72 hours; adult and child over 2 years currently\r\ntreated with a strong opioid analgesic, initial dose based\r\non previous 24-hour opioid requirement (consult product literature)", "When starting, evaluation of the\r\nanalgesic effect should not be made before the system\r\nhas been worn for 24 hours (to allow for the gradual\r\nincrease in plasma-fentanyl concentration)\u2014previous\r\nanalgesic therapy should be phased out gradually from time of first\r\npatch application; if necessary dose should be adjusted at 48\u201372-hour\r\nintervals in steps of 12\u201325\u00a0micrograms/hour. More than one patch may\r\nbe used at a time (but applied at the same time to\r\navoid confusion)\u2014consider additional or alternative analgesic therapy\r\nif dose required exceeds 300\u00a0micrograms/hour (important: it may take up to 25 hours for the plasma-fentanyl concentration to decrease by 50%\u2014replacement opioid therapy should\r\nbe initiated at a low dose and increased gradually).", "In view of the long duration\r\nof action, patients who have had severe side-effects should be monitored\r\nfor up to 24 hours after patch removal", "Breakthrough pain, see under oral preparations", "(from oral morphine to transdermal\r\nfentanyl) see Prescribing in Palliative\r\nCare"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour."}, {"indications": "Indications\u00a0severe chronic pain, breakthrough pain; parenteral indications (section 15.1.4.3)", "name": "FENTANYL Tablets", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "FENTANYL", "Tablets"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also diabetes\r\nmellitus, impaired consciousness, cerebral tumour; see also %s\n(From Patches: British National Formulary)\nPatchesTransdermal fentanylFever or external heat\u00a0Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption)Respiratory depression\u00a0Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patientsCounselling\u00a0Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdosage. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.Prescriptions\u00a0Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write \u2018Fentanyl 25 patches\u2019 to prescribe patches that release fentanyl 25\u00a0micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. \u2018one patch to be applied every 72 hours\u2019. The total quantity of patches to be supplied should be written in words and figures.FentanylDurogesic DTrans\u00ae", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; also\r\nabdominal pain, dyspepsia, diarrhoea, gastro-oesophageal reflux disease,\r\nstomatitis, anorexia, hypertension, vasodilation, dyspnoea, aesthenia,\r\nmyoclonus, anxiety, tremor, appetite changes, rhinitis, pharyngitis,\r\nparaesthesia, application-site reactions; less commonly ileus, flatulence, hypoventilation, impaired concentration, impaired\r\ncoordination, amnesia, speech disorder, malaise, seizures, pyrexia,\r\nthirst, blood disorders (including thrombocytopenia), chills; rarely hiccups; very rarely arrhythmia,\r\napnoea, haemoptysis, ataxia, delusions, bladder pain", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202699.htm", "doses": ["Chronic intractable pain, by transdermal route, apply to dry, non-irritated, non-irradiated, non-hairy skin on\r\ntorso or upper arm, removing after 72 hours and siting replacement\r\npatch on a different area (avoid using the same area for several days). adult over 16 years not currently treated with a strong opioid analgesic (but see Transdermal Fentanyl), initial dose, one \u201812\u2019 or \u201825\u00a0micrograms/hour\u2019\r\npatch replaced after 72 hours; adult and child over 2 years currently\r\ntreated with a strong opioid analgesic, initial dose based\r\non previous 24-hour opioid requirement (consult product literature)", "When starting, evaluation of the\r\nanalgesic effect should not be made before the system\r\nhas been worn for 24 hours (to allow for the gradual\r\nincrease in plasma-fentanyl concentration)\u2014previous\r\nanalgesic therapy should be phased out gradually from time of first\r\npatch application; if necessary dose should be adjusted at 48\u201372-hour\r\nintervals in steps of 12\u201325\u00a0micrograms/hour. More than one patch may\r\nbe used at a time (but applied at the same time to\r\navoid confusion)\u2014consider additional or alternative analgesic therapy\r\nif dose required exceeds 300\u00a0micrograms/hour (important: it may take up to 25 hours for the plasma-fentanyl concentration to decrease by 50%\u2014replacement opioid therapy should\r\nbe initiated at a low dose and increased gradually).", "In view of the long duration\r\nof action, patients who have had severe side-effects should be monitored\r\nfor up to 24 hours after patch removal", "Breakthrough pain, see under oral preparations", "(from oral morphine to transdermal\r\nfentanyl) see Prescribing in Palliative\r\nCare", "Name[Effentora\u00ae (Cephalon)  ] Tablets (buccal), fentanyl, sugar-free\r\n(as citrate) 100\u00a0micrograms, net price 4-tab pack = \u00a319.96,\r\n28-tab pack = \u00a3139.72; 200\u00a0micrograms, 4-tab pack = \u00a319.96, 28-tab\r\npack = \u00a3139.72; 400\u00a0micrograms, 4-tab pack = \u00a319.96, 28-tab pack =\r\n\u00a3139.72; 600\u00a0micrograms, 4-tab pack = \u00a319.96; 800\u00a0micrograms, 4-tab\r\npack = \u00a319.96, 28-tab pack = \u00a3139.72. \r\n    Label:\r\n    2, counselling, administrationElectrolytes: Na+ 0.35\u00a0mmol/100\u00a0microgram\r\ntablet, Na+ 0.70\u00a0mmol/tablet (all other strengths)Dose\u00a0breakthrough pain in patients receiving opioid therapy\r\nfor chronic cancer pain, adult over\r\n18 years, initially 100\u00a0micrograms repeated if necessary 30 minutes\r\nafter first dose (no more than 2 dose units for each pain episode);\r\nadjust dose according to response\u2014consult product literature; max.\r\n800\u00a0micrograms per episode of breakthrough pain; leave at least 4\r\nhours between treatment of episodes of breakthrough pain during titrationCounselling\u00a0Place tablet between cheek and gum\r\nand leave to dissolve; if more than 1 tablet required, place second\r\ntablet on the other side of the mouth; tablet may alternatively be\r\nplaced under the tongue (sublingually)The Scottish Medicines\r\nConsortium has advised that Effentora\u00ae buccal tablets should\r\nbe restricted for the management of breakthrough pain in adult patients\r\nusing opioid therapy for chronic cancer pain, when other short-acting\r\nopioids are unsuitable"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour."}, {"indications": "Indications\u00a0severe chronic pain, breakthrough pain; parenteral indications (section 15.1.4.3)", "name": "FENTANYL - ANALGESICS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "FENTANYL"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also diabetes\r\nmellitus, impaired consciousness, cerebral tumour; see also %s\n(From Patches: British National Formulary)\nPatchesTransdermal fentanylFever or external heat\u00a0Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption)Respiratory depression\u00a0Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patientsCounselling\u00a0Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdosage. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.Prescriptions\u00a0Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write \u2018Fentanyl 25 patches\u2019 to prescribe patches that release fentanyl 25\u00a0micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. \u2018one patch to be applied every 72 hours\u2019. The total quantity of patches to be supplied should be written in words and figures.FentanylDurogesic DTrans\u00ae", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; also\r\nabdominal pain, dyspepsia, diarrhoea, gastro-oesophageal reflux disease,\r\nstomatitis, anorexia, hypertension, vasodilation, dyspnoea, aesthenia,\r\nmyoclonus, anxiety, tremor, appetite changes, rhinitis, pharyngitis,\r\nparaesthesia, application-site reactions; less commonly ileus, flatulence, hypoventilation, impaired concentration, impaired\r\ncoordination, amnesia, speech disorder, malaise, seizures, pyrexia,\r\nthirst, blood disorders (including thrombocytopenia), chills; rarely hiccups; very rarely arrhythmia,\r\napnoea, haemoptysis, ataxia, delusions, bladder pain", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201310.htm", "doses": ["Chronic intractable pain, by transdermal route, apply to dry, non-irritated, non-irradiated, non-hairy skin on\r\ntorso or upper arm, removing after 72 hours and siting replacement\r\npatch on a different area (avoid using the same area for several days). adult over 16 years not currently treated with a strong opioid analgesic (but see Transdermal Fentanyl), initial dose, one \u201812\u2019 or \u201825\u00a0micrograms/hour\u2019\r\npatch replaced after 72 hours; adult and child over 2 years currently\r\ntreated with a strong opioid analgesic, initial dose based\r\non previous 24-hour opioid requirement (consult product literature)", "When starting, evaluation of the\r\nanalgesic effect should not be made before the system\r\nhas been worn for 24 hours (to allow for the gradual\r\nincrease in plasma-fentanyl concentration)\u2014previous\r\nanalgesic therapy should be phased out gradually from time of first\r\npatch application; if necessary dose should be adjusted at 48\u201372-hour\r\nintervals in steps of 12\u201325\u00a0micrograms/hour. More than one patch may\r\nbe used at a time (but applied at the same time to\r\navoid confusion)\u2014consider additional or alternative analgesic therapy\r\nif dose required exceeds 300\u00a0micrograms/hour (important: it may take up to 25 hours for the plasma-fentanyl concentration to decrease by 50%\u2014replacement opioid therapy should\r\nbe initiated at a low dose and increased gradually).", "In view of the long duration\r\nof action, patients who have had severe side-effects should be monitored\r\nfor up to 24 hours after patch removal", "Breakthrough pain, see under oral preparations", "(from oral morphine to transdermal\r\nfentanyl) see Prescribing in Palliative\r\nCare"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour."}]